Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Acquisition

Gujarat Themis Biosyn Acquisition Worth ₹1,722 Cr

Gujarat Themis Biosyn Limited is acquiring 13 branded generic products from Sanofi for Euro 158 million (approx. ₹1,722.2 Crore). The asset-light acquisition targets markets in Europe, Middle East, and Africa. The deal strengthens GTBL's global anti-infective platform and is expected to conclude by December 2026.

Key figures
Value₹1,722 Cr
Execution periodBy 31/12/2026
Source

NSE filing, NSE: GUJTHEM. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Gujarat Themis Biosyn Ltd: key numbers

Share price
₹355.55
Market cap
₹4,628 Cr
Revenue (annual)
₹165.8 Cr
Net profit (annual)
₹46.68 Cr
P/E (TTM)
95.0×Sector 46.1×
Promoter holding
59.33%-11.53% QoQ
FII holding
3.80%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Gujarat Themis Biosyn Ltd

All →

Other acquisition announcements

All →